Abstract
In 1958 a new therapy for depressions was introduced: medication with antidepressants. Almost simultaneously, but independendy, two types of compounds with an antidepressant effect were discovered: the tricyclic antidepressants (prototype: imipramine) and the monoamine oxidase inhibitors (MAOIs*) prototype: iproniazide). Previously, only amphetamine derivatives and opiates had been available for antidepressant medication. The effect of amphetamines on affective life was variable and brief, and often followed by a hangover; opiates actually acted mainly on anxiety and agitation. The antidepressants, with an effect on mood regulation which in suitable cases was primary and lasting, represented a new pharmacothera-peutic principle.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- CA:
-
catecholamines
- 4-CA:
-
4-chloramphetamine
- CMA:
-
4-chloro-N-methylamphetamine
- COMT:
-
catechol-O-methyltransferase
- cyclic AMP:
-
cyclic adenosine monophosphate
- DA:
-
dopamine
- Dopa:
-
dihydroxyphenylalanine
- DOPS:
-
dihy-droxyphenylserine
- ECT:
-
electroconvulsive therapy
- 5-HIAA:
-
5-hydroxyindoleacetic acid
- 5-HTP:
-
5-hydroxytryptophan
- HVA:
-
homovanilic acid
- IA:
-
indoleamine
- MA:
-
monoamine
- MAO:
-
monoamine oxidase
- MAOI:
-
monoamine oxidase inhibitor
- MHPG:
-
3-meth-oxy-4-hydroxyphenyl glycol
- α-MT:
-
α-methyl-p-tyrosine
- NA:
-
noradrenaline
- PCPA:
-
p-chloro-phenylalanine
- PEA:
-
phenylethylamine
- TRH:
-
thyrotropin releasing hormone
- VMA:
-
vanilylmandelic acid (3-methoxy-4-hydroxymandelic acid).
References
Abdullah, Y. H., and Hamadah, K., 1970. 3′5′-Cyclic adenosine monophosphate in depression and mania, Lancet1:378–381.
Alarcon, R. de, and Carney, M. W. P., 1969, Severe depressive mood changes following slow-release intramuscular fluphenazine injection, Br. Med. J.3:564–567.
Altman, K., and Greengard, O., 1966, Correlation of kynurenine excretion with liver tryptophan pyrrolase levels in disease and after hydrocortisone induction, J. Clin. Invest.45:1527–1534.
Andén, N. E., Rubenson, A., Fuxe, K., and Hökfelt, T., 1967, Evidence for dopamine receptor stimulation by apomorphine, J. Pharm. Pharmacol.19:627–629.
Andén, N. E., Corrodi, H., Fuxe, K., and Hökfelt, T., 1968, Evidence for a central 5-hydroxytryptamine receptor stimulation by lysergic acid diethylamine, Br. J. Pharmacol.34:1–7.
Andén, N. E., Butcher, S. G., Corrodi, H., Fuxe, K., and Ungerstedt, U., 1970, Receptor activity and turnover of dopamine and noradrenaline after neuroleptics, Eur. J. Pharmacol.11:303–314.
Andén, N. E., Corrodi, H., and Fuxe, K., 1972a, Effect of neuroleptic drugs on central catecholamine turnover assessed using tyrosine- and dopamine-β-hydroxylase inhibitors, J. Pharm. Pharmacol.24:177–182.
Andén, N. E., Engel, J., and Rubensson, A., 1972b, Central decarboxylation and uptake of l-dopa, Naunyn-Schmiedebergs Arch. Pharmakol.273:11–26.
Andersson, H., and Roos, B.-E., 1968, 5-Hydroxyindoleacetic acid in ventricular cerebrospinal fluid and brain of normal and hydrocephalic dogs after administration of 5-hydroxytryptophan, Acta Pharmacol.26:531–538.
Andersson, H., and Roos, B.-E., 1969, 5-Hydroxyindoleacetic acid in cerebrospinal fluid of hydrocephalic children, Acta Paediatr.58:601–608.
Angel, C., Deluca, D. C., and Murphree, O. D., 1976, Probenecid-induced accumulation of cyclic nucleotides, 5-hydroxyindoleacetic acid, and homovanillic acid in cisternal spinal fluid of genetically nervous dogs, Biol. Psychiatry11:743–753.
Angst, J., 1966, Zur Äetiologie und Nosologie endogener depressiver Psychosen: Eine genetische, soziologische und klinische Studie, Springer-Verlag, Berlin.
Angst, J., Baastrup, P., Grof, P., Hippius, H., Pöldinger, W., and Weis, P., 1973, The course of monopolar depression and bipolar psychoses, Psychiatr. Neurol. Neurochir.76:489–500.
Anton-Tay, F., and Wurtman, R. J., 1971, Brain monoamines and endocrine function, in: Frontiers in Neuroendocrinology (L. Martini and W. F. Ganong, eds.), pp. 45–66, Oxford University Press, New York.
Åsberg, M., Bertilsson, L., Tuck, D., Cronholm, B., and Sjöqvist, F., 1972, Indolamine metabolites in the cerebrospinal fluid of depressed patients before and during treatment with nortriptyline, Clin. Pharmacol. Ther.14:277–286.
Åsberg, M., Thorén, P., Träskman, L., Bertilsson, L., and Ringberger, V., 1976, Serotonin depression—A biochemical subgroup within the affective disorders? Science191:478–480.
Ashcroft, G. W., and Sharman, D. F., 1960, 5-Hydroxyindoles in human cerebrospinal fluids, Nature (London)186:1050–1051.
Ashcroft, G. W., Crawford, T. B. B., Eccleston, D., Sharman, D. F., NcDougall, E. J., Stanton, J. B., and Binns, J. K., 1966, 5-Hydroxyindole compounds in the cerebrospinal fluid of patients with psychiatric or neurological diseases, Lancet2:1049–1052.
Ashcroft, G. W., Dow, R. C., and Moir, A. T. B., 1968, The active transport of 5-hydroxyindole-3-acetic acid and 3-methoxy-4-hydroxypheny1acetic acid from a recircu-latory perfusion system of the cerebral ventricles of the unanaesthetized dog, J. Physiol.199:397–424.
Ashcroft, G. W., Crawford, T. B. B., Dow, R. C., and Moir, A. T. B., 1969, Release of amine metabolite into ventricular perfusion fluid as an index for turnover, in: Metabolism of Amines in the Brain (G. Hooper, ed.), pp. 65–69, MacMillan, London.
Ashcroft, G. W., Eccleston, D., Murray, L. G., Glen, A. I. M., Crawford, T. B. B., Pullar, I. A., Shields, P. J., Walter, D. S., Blackburn, I. M., Connechan, J., and Lonergan, M., 1972, Modified amine hypothesis for the etiology of affective illness, Lancet2:573–577.
Ashcroft, G. W., Blackburn, I. M., Eccleston, D., Glen, A. I. M., Hartley, W., Kinloch, N. E., Lonergan, M., Murray, L. G., and Pullar, I. A., 1973a, Changes on recovery in he concentrations of tryptophan and the biogenic amine metabolites in the cerebrospinal fluid of patients with affective illness, Psychol. Med.3:319–325.
Ashcroft, G. W., Crawford, T. B. B., Cundall, R. L., Davidson, D. L., Dobson, J., Dow, R. C., Eccleston, D., Loose, R. W., and Pullar, I. A., 1973b, 5-Hydroxytryptamine metabolism in affective illness: The effect of tryptophan administration, Psychol. Med.3:326–332.
Axelrod, J., 1966, Methylation reactions in the formation and metabolism of catecholamines and other biogenic amines, Pharmacol. Rev.18:95–113.
Axelrod, J., 1972, Dopamine-β-hydroxylase: Regulation of its synthesis and release from nerve terminals, Pharmacol. Rev.24:233–243.
Axelrod, J., and Cohn, C. K., 1971, Methyl transferase enzymes in red blood cells, J. Pharmacol. Exp. Ther.176:650–654.
Baldessarini, R. J., and York, C., 1970, Effects of lithium and pH on synaptosomal metabolism of noradrenaline, Nature (London)228:1301–1303.
Banki, C. M., 1977, Correlation between cerebrospinal fluid amine metabolites and psychomotor activity in affective disorders, J. Neurochem.28:255–257.
Barkai, A., Glusman, M., and Rapport, M. M., 1972, Serotonin turnover in the intact cat brain, J. Pharmacol. Exp. Ther.181:28–35.
Bartholini, G., and Pletscher, A., 1968, Cerebral accumulation and metabolism of C14-dopa after selective inhibition of peripheral decarboxylase, J. Pharmacol. Exp. Ther.161:14–20.
Bartholini, G., Pletscher, A., and Tissot, R., 1966, On the origin of homovanillic acid in the cerebrospinal fluid, Experientia22:609–610.
Becker, J., 1974, Depression: Theory and Research, Winston, Washington, D.C.
Beckmann, H., and Goodwin, F. K., 1975, Antidepressant response to tricyclics and urinary MHPG in unipolar patients, Arch. Gen. Psychiatry32:17–21.
Beckmann, H., St.-Laurent J., and Goodwin, F. K., 1975, The effect of lithium on urinary MHPG in unipolar and bipolar depressed patients, Psychopharmacologia42:277–282.
Benkert, O., Renz, A., Marano, C., and Matussek, N., 1971, Altered tyrosine daytime plasma levels in endogenous depressive patients, Arch. Gen. Psychiatry25:359–363.
Benkert, O., Martschke, D., and Gordon, A., 1974, Comparison of TRH, L.H.-R.H. and placebo in depression, Lancet2:1146.
Berg, G. R., and Glinsmann, W. H., 1970, Cyclic AMP in depression and mania, Lancet1:834.
Bernheimer, H., and Hornykiewicz, O., 1964, Das Verhalten des Dopamine Metaboliten Homovanillinsäure im Gehirn von Normalen und Parkinsonkranken Menschen, Arch. Exp. Pathol. Pharmakol247:305–306.
Bernheimer, H., Birkmayer, W., and Hornykiewicz, O., 1966, Homovanillinsäure in Liquor cerebrospinalis: Untersuchungen beim Parkinson-Syndrom und anderen Erkrankungen des ZNS, Wien. Klin. Wochenschr.78:417–419.
Bertaccini, G., 1959, Effect of convulsant treatment on the 5-hydroxytryptamine content of brain and other tissues of the rat, J. Neurochem.4:217–222.
Bertilsson, L., Åsberg, M., and Thorén, P., 1974, Differential effect of chlorimipramine and nortriptyline on metabolites of serotonine and noradrenaline in the cerebrospinal fluid of depressed patients, Eur. J. Clin. Pharmacol.7:365–368.
Bindler, E. H., Wallach, M. B., and Gershon, S., 1971, Effect of lithium on the release of 14C-norepinephrine by nerve stimulation from the perfused cat spleen, Arch. Int. Pharmacodyn. Ther.190:150–154.
Birkmayer, W., and Hornykiewicz, O., 1962, Der L-dioxyphenylalanin(-L-Dopa)-effekt beim Parkinson-Syndrom des Menschen: Zur Pathogenese und Behandlung der Parkinson-Akinese, Arch. Psychiatr. Nervenkrankh.203;560–574.
Birkmayer, W., and Linauer, W., 1970, Störung des Tyrosin- und Tryptophanmetabolismus bei Depression, Arch. Psychiatr. Nervenkrankh.213:377–387.
Blaschko, H., Burn, J. H., and Langemann, H., 1950, The formation of noradrenaline from dihydroxyphenylderine, Br. J. Pharmacol.5:431–437.
Bliss, E. L., Thatcher, W., and Ailion, J., 1972, Relationship of stress to brain serotonin and 5-hydroxyindoleacetic acid, J. Psychiatr. Res.9:71–80.
Bockar, J., Roth, R., and Heninger, G., 1974, Increased human platelet monoamine oxidase activity during lithium carbonate therapy, Life Sci.15:2109–2118.
Bohacek, N., 1973, Depression-inducing potential of neuroleptics, in: Aspects of Depression (M. Lader and R. Garcia, eds.), pp. 225–231, World Psychiatric Association, Madrid.
Bond, P. A., Jenner, F. A., and Sampson, G. A., 1972, Daily variations of the urine content of 3-methoxy-4-hydroxyphenylglycol in two manic depressive patients, Psychol. Med.2:81–85.
Bourne, H. R., Bunney, W. E., Jr., Colburn, R. W., Davis, J. M., Davis, J. N., Shaw, D. M., and Coppen, A. J., 1968, Noradrenaline, 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in hindbrain of suicidal patients, Lancet2:805–808.
Bowers, M. B., Jr., 1969, Deficient transport mechanism for the removal of acid monoa mine metabolites from cerebrospinal fluid, Brain Res.15:522–524.
Bowers, M. B., Jr., 1972a, Cerebrospinal fluid 5-hydroxyindoleacetic acid (5-HIAA) and homovanillic acid (HVA) following probenecid in unipolar depressives treated with amitriptyline, Psychopharmacologia23:26–33.
Bowers, M. B., Jr., 1972b, Acute psychosis induced by psychomimetic drug abuse. II. Neurochemical findings, Arch. Gen. Psychiatry27:440–442.
Bowers, M. B., Jr., 1972c, Clinical measurements of central dopamine and 5-hydroxytryptamine metabolism: Reliability and interpretation of cerebrospinal fluid acid monoamine metabolite measures, Neuropharmacology11:101–111.
Bowers, M. B., Jr., 1973, 5-Hydroxyindoleacetic acid (5-HIAA) and homovanillic acid (HVA) following probenecid in acute psychotic patients treated with phenothiazines, Psychopharmacologia28:309.
Bowers, M. B., Jr., and Gerbode, F., 1968a, Relationship of monoamine metabolites in human cerebrospinal fluid to age, Nature (London)219:1256–1257.
Bowers, M. B., Jr., and Gerbode, F., 1968b, CSF 5-HIAA. Effects of probenecid and parachlorophenylalanine, Life Sci.7:773–776.
Bowers, M. B., Jr., Heninger, G. R., and Gerbode, F., 1969, Cerebrospinal fluid 5-hydroxyindoleacetic acid and homovanillic acid in psychiatric patients, Int. J. Neuropharmacol.8:255–262.
Boyland, E., 1958, The biochemistry of cancer of the bladder, Br. Med. Bull. 14: 153–158.
Boyland, E.British Medical Journal, 1966, Methyldopa in hypertension, 1:119–120.
Brodie, H. K. H., Murphy, D. L., Goodwin, F. K., and Bunney, W. E., Jr., 1971, Catecholamines and mania: The effect of alpha-methyl-para-tyrosine on manic behavior and catecholamine metabolism, Clin. Pharmacol. Ther.12:219–224.
Brodie, H. K. H., Sack, R., and Siever, L., 1973, Clinical studies of 5-hydroxytryptophan in depression, in: Serotonin and Behavior (J. Barchas and E. Usdin, eds.), pp. 549–559. Academic Press, New York.
Brown, G. W., Sklair, F., Harris, T. O., and Birley, J. L. T., 1973, Life-events and psychiatric disorder. Part I. Some methodological issues, Psychol. Med.3:74–87.
Bruinvels, J., 1972, Inhibition of the biosynthesis of 5-hydroxytryptamine in rat brain by imipramine, Eur. J. Pharmacol.20:231–237.
Bulat, M., and Zivkovic, B., 1971, Origin of 5-hydroxyindoleacetic acid in the spinal fluid, Science173:738–740.
Bulat, M., and Zivkovic, B., 1973, Penetration of 5-hydroxyindoleacetic acid across the blood-cerebrospinal fluid barrier, J. Pharm. Pharmacol.25:178–179.
Bullpitt, C. J., and Dollery, C. T., 1973, Side effects of hypotensive agents evaluated by a self-administered questionnaire, Br. Med. J.3:485–490.
Bunney, W. E., Jr., and Davis, J. M., 1965, Norepinephrine in depressive reactions: A review, Arch. Gen. Psychiatry13:483–494.
Bunney, W. E., Jr., Murphy, D. L., and Goodwin, F. K., 1970, The switch process from depression to mania: Relationship to drugs which alter brain amines, Lancet1:1022–1027.
Bunney, W. E., Jr., Brodie, H. K. H., Murphy, D. L., and Goodwin, F. K., 1971, Studies of alpha-methyl-para-tyrosine, L-dopa and L-tryptophan in depression and mania, Am. J. Psychiatry127:872–881.
Bunney, W. E., Jr., Walters, J. R., Roth, R. H., and Aghajanian, G. K., 1973, Dopaminergic neurons: Effect of antipsychotic drugs and amphetamine on single cell activity, J. Pharmacol. Exp. Ther.185:560–571.
van den Burg, W., van Praag, H. M., Bos, E. R. H., van Zanten, A. K., Piers, D. A., and Doorenbos, H., 1975, TRH as a possible quick-acting but short-lasting antidepressant, Psychol. Med.5:404–412.
van den Burg, W., van Praag, H. M., Bos, E. R. H., van Zanten, A. K., Piers, D. A., and Doorenbos, H., 1976, TRH by slow, continuous infusion: An antidepressant? Psychol. Med.6:393–397.
Butcher, L. L., and Engel, J., 1969, Behavioral and biochemical effects of L-dopa after peripheral decarboxylase inhibition, Brain Res.15:233–242.
Calne, D. B., Karoum, F., Ruthven, C. R. J., and Sandler, M., 1969, The metabolism of orally administered L-dopa in parkinsonism, Br. J. Pharmacol.37:57–68.
Campanini, T., Catalano, A., Derisio, C., and Mardighian, G., 1970, Vanilmandelic aciduria in the different clinical phases of manic depressive psychoses, Br. J. Psychiatry116:435–436.
Carlsson, A., Falck, B., Fuxe, K., and Hillarp, N. A., 1964, Cellular localization of monoamines in the spinal cord, Acta Physiol. Scand.60:112–119.
Carlsson, A., Fuxe, K., Hamberger, B., and Lindqvist, M., 1966, Biochemical and histochemical studies on effects of imipramine-like drugs and (+) amphetamine on central and peripheral catecholamine neurons. Acta Physiol. Scand.67:481–497.
Carlsson, A., Corrodi, H., Fuxe, K., and Hökfelt, T., 1969a, Effect of antidepressant drugs on the depletion of intraneuronal brain 5-hydroxytryptamine stores caused by 4-methyl-α-ethyl-meta-tyramine. Eur. J. Pharmacol.5:357–366.
Carlsson, A., Corrodi, H., Fuxe, K., and Hökfelt, T., 1969b, Effects of some antidepressant drugs on the depletion of intraneuronal brain catecholamine stores caused by 4,α-dimethyl-meta-tyramine. Eur. J. Pharmacol.5:367–373.
Carman, J. S., Post, R. M., Teplitz, T. A., and Goodwin, F. K., 1974, Divalent cautions in predicting antidepressant response to lithium, Lancet2:1454.
Carney, M. W. P., and Sheffield, B. F., 1974, The effects of pulse ECT in neurotic and endogenous depression, Br. J. Psychiatry125:91–94.
Carney, M. W. P., Thakurdas, H., and Sebastian, J., 1969, Effects of imipramine and reserpine in depression, Psychopharmacologia14:349–350.
Carroll, B. J., 1971, Monoamine precursors in the treatment of depression, Clin. Pharmacol. Ther.12:743–761.
Carroll, B. J., and Dodge, J., 1971, L-Tryptophan as an antidepressant, Lancet1:915.
Carroll, B. J., Mowbray, R. M., and Davies, B. M., 1970, Sequential comparison of l-tryptophan with E.C.T. in severe depression, Lancet1:967–969.
Cazzullo, C. L., Mangoni, A., and Mascherpa, G., 1966, Tryptophan metabolism in affective psychoses, Br. J. Psychiatry112:157–162.
Charalampous, K. D., and Brown, S., 1967, A clinical trial of alpha-methyl-para-tyrosine in mentally ill patients, Psychopharmacologia11:422–429.
Chase, T. N., 1972, Serotonergic mechanisms in Parkinson’s disease, Arch. Neurol.27:354–356.
Chase, T. N., Gordon, E. K., and Ng, L. K. Y., 1973, Norepinephrine metabolism in the central nervous system of man: Studies using 3-methoxy-4-hydroxyphenylethylene glycol levels in cerebrospinal fluid, J. Neurochem.21:581–587.
Chodoff, P., 1972, The depressive personality. A critical review, Arch. Gen. Psychiatry27:666–673.
Claveria, L. E., Curzon, G., Harrison, M. J. G., and Kantamaneni, B. D., 1974, Amine metabolites in the cerebrospinal fluid of patients with disseminated sclerosis, J. Neurol. Neurosurg. Psychiatry37:715–718.
Cohn, C. K., Dunner, D. L., and Axelrod, J., 1970, Reduced catechol-O-methyltransferase activity in red blood cells of women with primary affective disorder, Science170:1323–1324.
Constantinides, J., Geissbühler, F., Gaillard, J. M., Hovaguimian, T., and Tissot, R., 1974, Enhancement of cerebral noradrenaline turnover by thyrotropin-releasing hormone: Evidence by fluorescence histochemistry, Experientia30:1182.
Coppen, A., 1967, Biochemistry of affective disorders, Br. J. Psychiatry113:1237–1264.
Coppen, A., Shaw, D. M., and Farrell, J. P., 1963, Potentiation of the antidepressive effects of a monoamine oxidase inhibitor by tryptophan, Lancet1:79–81.
Coppen, A., Shaw, D. M., and Malleson, A., 1965a, Changes in 5-hydroxytryptophan metabolism in depression, Br. J. Psychiatry11:105–107.
Coppen, A., Shaw, D. M., Malleson, A., Eccleston, E., and Gundy, G., 1965b, Tryptamine metabolism in depression, Br. J. Psychiatry111:996–998.
Coppen, A., Shaw, D. M., Herzberg, B., and Maggs, R., 1967, Tryptophan in treatment of depression, Lancet2:1178–1180.
Coppen, A., Prange, A. J., Whybrow, P. C., Noguera, R., and Paez, J. M., 1969, Methysergide in mania, Lancet2:338–340.
Coppen, A., Prange, A. J., Whybrow, P. C., and Noguera, R., 1972a, Abnormalities of indolamines in affective disorders, Arch. Gen. Psychiatry26:474–478.
Coppen, A., Brooksbank, B. W. L., and Peet, M., 1972b, Tryptophan concentration in the cerebrospinal fluid of depressive patients, Lancet1:1393.
Coppen, A., Eccleston, E. G., and Peet, M., 1973, Total and free tryptophan concentration in the plasma of depressive patients, Lancet2:60–63.
Coppen, A., Brooksbank, B. W. G., and Eccleston, E., 1974a, Tryptophan metabolism in depressive illness, Psychol. Med.4:164–173.
Coppen, A., Montgomery, S., Peet, M., Bailey, J., Marks, V., and Woods, P., 1974b, Thyrotropin-releasing hormone in the treatment of depression, Lancet2:433–435.
Corrodi, H., and Fuxe, K., 1969, Decreased turnover in central 5-HT nerve terminals induced by antidepressant drugs of the imipramine type, Eur. J. Pharmacol.7:56–59.
Corrodi, H., Fuxe, K., Hökfelt, T., and Schou, M., 1967, Effect of lithium on cerebral monoamine neurons, Psychopharmacologia11:345–353.
Corrodi, H., Fuxe, K., and Schou, M., 1969, The effect of prolonged lithium administration on cerebral monoamine neurons in the rat, Life Sci.8:643–651.
Cotzias, M., Woert, M. H. van, and Schiffer, L. M., 1967, Aromatic amino acids and modifications of parkinson, N. Engl. J. Med.276:374–379.
Cramer, H., Goodwin, F. K., Post, R. M., and Bunney, W. E., Jr., 1972, Effects of probenecid and exercise on cerebrospinal fluid cyclic AMP in affective illness, Lancet1:1346–1347.
Cremata, V. Y., and Koe, B. K., 1966, Clinical-pharmacological evaluation of p-chlorophenylalanine: New serotonin-depleting agent, Clin. Pharmacol. Ther.7:768–776.
Creveling, C. R., Daly, J., Tokuyama, T., and Witkop, B., 1968, The combined use of α-methyltyrosine and threo-dihydroxyphenylserine. Selective reduction of dopamine levels in the central nervous system, Biochem. Pharmacol.7:65–70.
Crout, J. R., and Sjoerdsma, A., 1959, Clinical and laboratory significance of serotonin and catecholamine in bananas, N. Engl. J. Med.261:23–26.
Curzon, G., 1969, Tryptophan pyrrolase—a biochemical factor in depressive illness?, Br. J. Psychiatry115:1367–1374.
Curzon, G., and Green, A. R., 1968, Effect of hydrocortisone on rat brain 5-hydroxytrypt-amine, Life Sci.7:657–663.
Curzon, G., Gumpert, E. J. W., and Sharpe, D. M., 1971, Amine metabolite in the lumbar cerebrospinal fluid of humans with restricted flow of cerebrospinal fluid, Nature (London) New Biol.231:189–191.
Curzon, G., Friedel, J., and Knott, P. J., 1973, The effect of fatty acids on the binding of tryptophan to plasma protein, Nature (London)242:198–200.
Davson, H., 1967, Physiology of the Cerebrospinal Fluid, Churchill, London.
Deleon-Jones, F., Maas, J. W., Dekirmenjian, H., and Sanchez, J., 1975, Diagnostic subgroups of affective disorders and their urinary excretion of catecholamine metabolites, Am. J. Psychiatry132:1141–1148.
Denker, S. J., Malm, U., Roos, B.-E., and Werdinius, B., 1966, Acid monoamine metabolites of cerebrospinal fluid in mental depression and mania, J. Neurochem.13:1545–1548.
Despopoulos, A., and Weissbach, H., 1957, Renal metabolism of 5-hydroxyindoleacetic acid, Am. J. Physiol.189:548–550.
Dewhurst, W. G., 1968, Methysergide in mania, Nature (London)219:506–507.
Doepfner, W., 1962, Biochemical observations on LSD-25 and Deseril, Experientia18:256–257.
Doepfner, W., and Cerletti, A. M. S., 1958, Comparison of lysersic acid derivatives and antihistamines as inhibitors of the edema provoked in the rat’s paw by serotonin, Int. Arch. Allerg.12:89–97.
Dousa, T., and Hechter, O., 1970, Lithium and brain adenylcyclase, Lancet1:834–835.
Dunner, D. L., and Fieve, R. R., 1975, Affective disorder. Studies with amine precursors, Am. J. Psychiatry132:180–183.
Dunner, D. L., and Goodwin, F. K., 1972, Effect of L-tryptophan on brain serotonin metabolism in depressed patients, Arch. Gen. Psychiatry26:364–366.
Dunner, D. L., Cohn, C. K., Gershon, E. S., and Goodwin, F. K., 1971, Differential catechol-O-methyltransferase activity in unipolar and bipolar affective illness, Arch. Gen. Psychiatry25:348–353.
Duvoisin, R. C., Yahr, M. D., and Cote, L. D., 1969, Pyridoxine reversal of l-DOPA effects in parkinsonism, Trans. Am. Neurol. Assoc.94:81–84.
Ebert, M. H., Baldessarini, R. J., Lipinski, J. F., and Berv, K., 1973, Effects of electroconclusive seizures on amine metabolism in the rat brain, Arch. Gen. Psychiatry29:397–401.
Eccleston, D., Ashcroft, G. W., Moir, A. T. B., Parker-Rhodes, A., Lutz, W., and O’Mahoney, D. P., 1968, A comparison of 5-hydroxyindoles in various regions of dog brain and cerebrospinal fluid, J. Neurochem.15:947–957.
Eccleston, D., Loose, R., Pullar, J. A., and Sugden, R. F., 1970a, Exercise and urinary excretion of cyclic AMP, Lancet2:612–613.
Eccleston, D., Ashcroft, G. W., Moir, A. T. B., Parker-Rhodes, A., Lutz, W., and O’Mahoney, D. P., 1968, A comparison of 5-hydroxyindoles in various regions of dog brain and cerebrospinal fluid, J. Neurochem.15:947–957.
Edwards, D. J., and Burns, M. O., 1974, Effects of tricyclic antidepressants upon human platelet monoamineoxidase, Life Sci.15:2045–2048.
Ehringer, H., and Hornykiewicz, O., 1960, Verteilung von Noradrenalin und Dopamine (3-hydroxytryptamine) im Gehirn des Menschen und Ihr Verhalten bei Erkrankungen des extrapyramidalen Systems, Klin. Wochenschr.38:1236–1239.
Eleftherion, B. E., and Boehlke, K. W., 1967, Brain monoamine oxidase in mice after exposure to agression and defeat, Science155:1693–1694.
El-Yousef, M. K., Janowski, D. S., Davis, J. M., and Sekerke, H. J., 1973, Induction of severe depression by physostigmine in marijuana intoxicated individuals, Br. J. Addict.68:321–326.
Engel, J., Hanson, L. C. F., and Roos, B.-E., 1971, Effect of electroshock on 5-HT metabolism in rat brain, Psychopharmacologia20:197–200.
Engelman, K., Lovenberg, W., and Sjoerdsma, A., 1967, Inhibition of serotonin synthesis by para-chlorophenylalanine in patients with the carcinoid syndrome, N. Engl. J. Med. 277:1103–1108.
Erspamer, V., 1966, Occurrence of indolealkylamines in nature, in: 5-Hydroxytryptamine and Related Indolealkylamines (V. Erspamer, ed.), pp. 132–181, Springer-Verlag, Berlin—Heidelberg—New York.
Everett, G. M., and Borcherding, J. W., 1970, L-Dopa: Effect on concentrations of dopamine, norepinephrine and serotonin in brains of mice, Science168:849–850.
Extein, I., Korf, J., Roth, R. H., and Bowers, M. B., Jr., 1973, Accumulation of 3-methoxy-4-hydroxyphenylglycol-sulphate in rabbit cerebrospinal fluid following probenecid, Brain Res. 54:403–407.
Fann, W. E., Davis, J. M., Janowski, D. S., Cavanaugh, J. H., Kaufman, J. S., Griffith, J. D., and Oates, J. A., 1972, Effects of lithium on adrenergic function in man, Clin. Pharmacol. Ther. 13:71–77.
Fernando, J. C., Joseph, M. H., and Curzon, G., 1975, Tryptophan plus a pyrrolase inhibitor for depression?, Lancet1:171.
Fernström, J. D., and Wurtman, R. J., 1971, Brain serotonin content: Physiological dependence on plasma tryptophan levels, Science173:149–152.
Fernström, J. D., and Wurtman, R. J., 1972, Brain serotonin content: Physiological regulation by plasma neutral amino acids, Science178:414–416.
Fieve, R. R., Platman, S. R., and Fliess, J. L., 1969, A clinical trial of methysergide and lithium in mania, Psychopharmacologia15:425–429.
Fischer, E., Heller, B., and Miro, A. N., 1968, β-Phenylethylamine in human urine, Arzneim.-Forsch. 18:1486.
Fischer, E., Spatz, H., Saavedra, J. M., Reggiani, H., Mior, A. H., and Heller, B., 1972a, Urinary elimination of phenylethylamine, Biol. Psychiatry5:139–147.
Fischer, E., Spatz, H., Heller, B., and Reggiani, H., 1972b, Phenylethylamine content of human urine and rat brain: Its alteration in pathological conditions and after drug administration, Experientia28:307–308.
Flentge, F., and Klaver, M. M., 1975, An investigation into the origin of choline in cerebrospinal fluid, Proceedings of the Federal Meetings, Utrecht, The Netherlands
Forn, J., and Valdecasas, F. G., 1971, The effects of lithium on brain adenyl cyclase activity, Biochem. Pharmacol. 20:2773–2779.
Friedman, E., and Gershon, S., 1973, Effects of lithium on brain dopamine, Nature (London)243:520–521.
Frey, H. H., and Magnussen, M. P., 1968, Different central mediation of the stimulant effects of amphetamine and its p-chloroanalogue, Biochem. Pharmacol. 17:1299–1308.
Fuller, R. W., and Molloy, B. B., 1974, Recent studies with 4-chloroamphetamine and some analogues, Adv. Biochem. Psychopharmacol. 10:195–205.
Fuller, R. W., Hines, C. W., and Mills, J., 1965, Lowering of brain serototonin level by chloroamphetamines, Biochem. Pharmacol. 14:483–488.
Fuller, R. W., Perry, K. W., and Molloy, B. B., 1974, Effect of an uptake inhibitor on serotonin metabolism in rat brain: Studies with 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenyl-propylamine (Lilly 110140), Life Sci. 15:1161–1171.
Fuxe, K., Butcher, L. L., and Engel, J., 1971, DL-5-Hydroxytryptophan-induced changes in central monoamine neurons after peripheral decarboxylase inhibition, J. Pharm. Pharmacol. 23:420–424.
Fyrö, B., Petterson, U., and Sedvall, G., 1975, The effect of lithium treatment on manic symptoms and levels of monoamine metabolites in cerebrospinal fluid of manic depressive patients, Psychopharmacologia44:99–103.
Garattini, S., Kato, R., Lamesta, L., and Valzelli, L., 1960, Electroshock, brain serotonin and barbiturate narcosis, Experientia16:156–157.
Garelis, E., and Sourkes, T. L., 1973, Sites of origin in the central nervous system of monoamine metabolites measured in human cerebrospinal fluid, J. Neurol. Neurosurg. Psychiatry4:625–629.
Garelis, E., Young, S. N., Lal, S., and Sourkes, T. L., 1974, Monoamine metabolites in lumbar CSF: The question of their origin in relation to clinical studies, Brain Res. 79:1–8.
Garside, R. F., Kay, D. W. K., Wilson, I. C., Deaton, I. D., and Roth, M., 1971, Depressive syndromes and the classification of patients, Psychol. Med. 1:333–338.
Genefke, I. K., 1972, The concentration of 5-HT in hypothalamus, grey and white brain substance in the rat after prolonged oral lithium administration, Acta Physiol. Scand. 48:400–404.
Gershon, S., Hekimian, L. J., Floyd, A., Jr., and Hollister, L. E., 1967, α-Methyl-p-tyrosine (AMT) in schizophrenia, Psychopharmacologia11:189–194.
Gershon, S., Goodwin, F. K., and Gold, P., 1970, Effect of L-tyrosine and L-dopa on norepinephrine (NE) turnover in rat brain in vivo, Pharmacologist12:268.
Glassman, A., 1969, Indoleamines and affective disorders, Psychosom. Med. 31:107–114.
Glassman, A., and Platman, S. R., 1969, Potentiation of a monoamine oxidase inhibitor by tryptophan, J. Psychiatr. Res. 7:83–88.
Godwin-Austen, R. B., Kantamaneni, B. D., and Curzon, G., 1971, Comparison of benefit from L-dopa in Parkinsonism with increase of amine metabolites in the CSF, J. Neurol. Neurosurg. Psychiatry34:219–223.
Goldstein, M., and Gerber, H., 1963, Phenolic alcohols in the brain after administration of dopa C14, Life Sci. 2:97–100.
Goodwin, F. K., 1972, Behavioral effects of l-DOPA in man, in: Psychiatric Complications of Medical Drugs (R. T. Shader, ed.), pp. 149–174, Raven Press, New York.
Goodwin, F. K., 1976, Discussion remarks, in: Neuroregulators and Psychiatric Disorders (E. Usdin, D. A. Hamburg, and Y. D. Barchas, eds.), p. 192, Oxford University Press, New York.
Goodwin, F. K., and Post, R. M., 1973, The use of probenecid in high doses for the estimation of central serotonin turnover in affective illness and addicts of methadone, in: Serotonin and Behavior (J. Barchas and E. Usdin, eds.), pp. 469–480, Academic Press, New York.
Goodwin, F. K., and Post, R. M., 1974, Cerebrospinal fluid amine metabolites in affective illness, J. Psychiatr. Res. 10:320.
Goodwin, F. K., Brodie, H. K. H., Murphy, D. L., and Bunney, W. E., Jr., 1970, L-Dopa, catecholamines and behavior: A clinical and biochemical study in depressed patients, Biol. Psychiatry2:341–366.
Goodwin, F. K., Dunner, D. L., and Gershon, S., 1971, Effect of l-dopa treatment on brain serotonin metabolism in depressed patients, Life Sci. 10:751–759.
Goodwin, F. K., Ebert, M. H., and Bunney, W. E., Jr., 1972a, Mental effects of reserpine in man: A review, in: Psychiatric Complications of Medical Drugs (R. I. Shader, ed.), pp. 73–101, Raven Press, New York.
Goodwin, F. K., Murphy, D. L., Dunner, D. L., and Bunney, W. E., Jr., 1972b, Lithium response in unipolar versus bipolar depression, Am. J. Psychiatry129:44–47.
Goodwin, F. K., Post, R. M., Dunner, D. L., and Gordon, E. K., 1973, Cerebrospinal fluid amine metabolism in affective illness: The probenecid technique, Am. J. Psychiatry130:73–79.
Gordon, E. K., and Oliver, J., 1971, 3-Methoxy-4-hydroxy-phenylethylene glycol in human cerebrospinal fluid, Clin. Chim. Acta. 35:145–150.
Gordon, E. K., Oliver, J., Goodwin, F. K., Chase, T. N., and Post, R. M., 1973, Effect of probenecid on free 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) and its sulphate in human cerebrospinal fluid, Neuropharmacology12:391–396.
Gottfries, C. G., and Roos, B.-E., 1969, Homovanillic acid and 5-hydroxyindoleacetic acid in the cerebrospinal fluid of patients with senile dementia, presenile dementia and parkinsonism, J. Neurochem. 16:1341–1345.
Gottfries, C. G., and Roos, B.-E., 1970, Homovanillic acid and 5-hydroxyindoleacetic acid in cerebrospinal fluid related to rated mental and motor impairment in senile and presenile dementia, Acta Psychiatr. Scand. 46:99–105.
Gottfries, C. G., and Roos, B.-E., 1973, Acid monoamine metabolites in cerebrospinal fluid from patients with presenile dementia (Alzheimer’s disease), Acta Psychiatr. Scand. 49:257–263.
Gottfries, C. G., Oreland, L., and Wiberg, A., 1974, Brain-levels of monoamine oxidase in depression, Lancet2:360.
Gottfries, C. G., Oreland, L., Wiberg, Å., and Wimblad, B., 1975, Lowered monoamine oxidase activity in brains from alcoholic suicides, J. Neurochem.25:667–673.
Grabowska, M., Antkiewicz, L., and Michaluk, J., 1974, The influence of quipanzine on the turnover rate of serotonin, Biol. Pharmacol. 23:3211–3212.
Grahame-Smith, D. G., 1971, Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan, J. Neurochem. 18:1053–1066.
Grahame-Smith, D. G., and Green, A. R., 1974, The role of brain 5-hydroxytryptamine in the hyperactivity produced in rats by lithium and monoamine oxidase inhibition, Br. J. Pharmacol. 52:19–26.
Green, A. R., and Curzon, G., 1968, Decrease of 5-hydroxytryptamine in the brain provoked by hydrocortisone and its prevention by Allopurinol, Nature (London)220:1095–1097.
Green, A. R., and Grahame-Smith, D. G., 1974, TRH potentiates behavioral changes following increased brain 5-hydroxy-tryptamine accumulation in rats, Nature (London)251:524–526.
Green, H., Greenberg, S. M., and Erickson, R. W., 1962, Effect of dietary phenylalanine and tryptophan upon the rat brain amine levels, J. Pharmacol. Exp. Ther. 136:174–178.
Greenspan, K., Schildkraut, J. J., Gordon, E. K., Levy, B., and Durell, J., 1969, Catecholamine metabolism in affective disorders. II. Norepinephrine, normetane-phrine, epinephrine, metanephrine and VMA excretion in hypomanic patients, Arch. Gen. Psychiatry21:710–716.
Greenspan, K., Schildkraut, J. J., Gordon, E. K., Baer, L., Aranoff, M. S., and Durell, J., 1970, Catecholamine metabolism in affective disorders. III. MHPG and other catecholamine metabolites in patients treated with lithium carbonate, J. Psychiatr. Res. 7:171–183.
Grof, P., and Foley, P., 1971, The superiority of lithium over methysergide in treating manic patients, Am. J. Psychiatry127:1573–1574.
Grote, S. S., Moses, S. G., Robins, E., Hudgens, R. W., and Croninger, A. B., 1974, A study of selected catecholamine-metabolizing enzymes: A comparison of depressive suicides and alcoholic suicides with controls, J. Neurochem. 23:791–802.
Gruen, P. H., Sacher, E. J., Altman, N., and Sassin, J., 1975, Growth hormone responses to hypoglycemia in postmenopausal depressed women, Arch. Gen. Psychiatry32:31–33.
Guldberg, H. C., Ashcroft, G. W., and Crawford, T. B. B., 1966, Concentrations of 5-hydroxyindoleacetic acid and homovanillic acid in the cerebrospinal fluid of the dog before and during treatment with probenecid, Life Sci. 5:1571–1575.
Hamadah, K., Holmes, H., Barker, G. B., Hartman, G. C., and Parke, D. V. W., 1972, Effect of electric convulsion therapy on urinary cyclic adenosine monophosphate, Br. Med. J. 111:439–441.
Hamilton, M., 1968, Some aspects of the long-term treatment of severe hypertension with methyldopa, Postgrad. Med. J. 44:66–69.
Harper, A. E., Benevenga, N. J., and Wolhueter, R. M., 1970, Effects of ingestion of disproportionate amounts of amino acids, Physiol. Rev. 50:428–558.
Haskovec, L., 1969, Methysergide in mania, Lancet2:902.
Haskovec, L., and Rysanek, K., 1967, The action of reserpine in imipramine-resistant depressive patients, Psychopharmacologia11:18–30.
Haskovec, L., and Soucek, K., 1968, Trial of methysergide in mania, Nature (London)219:507–508.
Hassler, R., Bak, I. J., and Kim, J. S., 1970, Unterschiedliche Endeerung des Speicheorte für Noradrenalin, Dopamine, und Serotonin als Wirkungsprinzip des Oxypertins, Nervenarzt. 41:105–118.
Hendley, E. D., and Welch, B. L., 1975, Electroconvulsive shock: Sustained decrease in norepinephrine uptake affinity in a reserpine model of depression, Life Sci. 16:45–54.
Herrington, K. N., Bruce, A., Johnstone, E. C., and Lader, M. H., 1974, Comparative trial of L-tryptophan and E.C.T. in severe depressive illness, Lancet2:731–734.
Hertting, G., and La Brosse, H., 1962, Bilary and urinary excretion of metabolites of 7 H3-epinephrine in the rat, J. Biol. Chem. 237:2291–2295.
Hertz, D., and Sulman, F. G., 1968, Preventing depression with tryptophan, Lancet1:531–532.
Hinsley, R. K., Norton, J. A., and Aprison, M. H., 1968, Serotonin, norepinephrine and 3,4-dihydroxyphenylethylamine in rat brain parts following electroconvulsive shock, J. Psychiatr. Res. 6:143–152.
Hirsch, S. R., Gaind, R., Rohde, P. D., Stevens, B. C., and Wing, J. K., 1973, Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: Double-blind placebo trial, Br. Med. J. 192:633–637.
Ho, A. K. S., Loh, H. H., Craves, F., Hitzeman, R. J., and Gershon, S., 1970, The effect of prolonged lithium treatment on the synthesis rat and turn-over of monoamines in brain regions of rats, Eur. J. Pharmacol. 10:72–78.
Hollister, L. E., Berger, P., Ogie, F. L., Arnold, R. C., and Johnson, A., 1974, Protirelin (TRH) in depression, Arch. Gen. Psychiatry31:468–470.
Horst, W. D., and Spirt, N., 1974, A possible mechanism for the antidepressant activity of thyrotropin releasing hormone, Life Sci. 15:1073–1082.
Hullin, R. P., Bailey, A. D., McDonald, R., Dransfield, G. A., and Milne, H. B., 1967, Variations in 11-hydroxycorticosteroids in depression and manic-depressive psychosis, Br. J. Psychiatry113:593–600.
Hunter, K. R., Boakes, A. J., Laurence, D. R., and Stern, G. M., 1970, Monoamine oxidase inhibitors and L-dopa, Br. Med. J. 3:388.
Janowski, D. S., El-Yousef, M. K., Davis, J. M., and Sekerke, H. J., 1972, A cholinergic adrenergic hypothesis of mania and depression, Lancet2:632–635.
Janowski, D. S., El-Yousef, M. K., Davis, J. M., and Sekerke, H. J., 1973, Parasympathetic suppression of manic symptoms by physostigmine, Arch. Gen. Psychiatry28:542–552.
Janowski, D. S., El-Yousef, M. K., and Davis, J. M., 1974, Acetylcholine and depression, Psychosom. Med. 36:248–257.
Jensen, K., Fruensgaard, K., Ahlfors, U. G., Pihkanen, T. A., Tuomikoski, S., Ose, E., Dencker, S. J., Lindberg, D., and Nagy, A., 1975, Tryptophan/imipramine in depression, Lancet2:920.
Jepson, J. B., Lovenberg, W., and Zaltzman, P., 1960, Amine metabolism studied in normal and Phenylketonuric humans by monoamine oxidase inhibition, Biochem. J. 74:5.
Jéquir, E., Lovenberg, W., and Sjoerdsma, A., 1967, Tryptophan hydroxylase inhibition: The mechanism by which p-chlorophenylalanine depletes rat brain serotonin, Mol. Pharmacol. 3:274–278.
Jimerson, D. C., Gordon, E. K., Post, R. M., and Goodwin, F. K., 1975, Central noradrenergic function in man: Vanillylmandelic acid in CSF, Brain Res. 99:434–439.
Johnson, P., Kitchin, A. H., Lowther, C. P., and Turner, R. W. D., 1966, Treatment of hypertension with methyldopa, Br. Med. J. 1:133–137.
Jonsson, L. E., Angard, E., and Gunne, L. M., 1971, Blockade of intravenous amphetamine euphoria in man, Clin. Pharmacol. Ther. 12:889–896.
Kane, F. J., 1970, Treatment of mania with cinanserin, an antiserontonin agent, Am. J. Psychiatry126:1020–1023.
Kansal, P. C., Buse, J., Talbert, O. R., and Buse, M. G., 1972, Effect of L-dopa on plasma growth hormone, insulin, and thyroxine, J. Clin. Endocrinol. Metab. 34:99–105.
Karki, N. T., 1956, Urinary excretion of noradrenaline and adrenaline in different age groups. Its diurnal variation and effect of muscular work on it, Acta Physiol. Scand. 39(Supl. 132): 5–96.
Kastin, A. J., Ehrensing, R. H., Schalch, D. S., and Anderson, M. S., 1972, Improvement in mental depression with decreased thyrotropin response after administration of thyrotropin-releasing hormone, Lancet2:740–742.
Katz, R. I., Chase, T. N., and Kopin, I. J., 1968, Evoked release of norepinephrine and serotonin from brain slices: Inhibition by lithium, Science162:466–467.
Keller, H. H., Bartholini, G., and Pletscher, A., 1973, Increase of 3-methoxy-4-hydroxyphenylethylene glycol in rat brain by neuroleptic drugs, Eur. J. Pharmacol. 23:183–186.
Keller, H. H., Bartholini, G., and Pletscher, A., 1974, Enchancement of noradrenaline turnover in rat brain by L-dopa, J. Pharm. Pharmacol. 26:649–651.
Kety, S. S., 1971, Brain amines and affective disorders, in: Brain Biochemistry and Mental Disease (B. T. Ho and W. M. McIsaac, eds.), pp. 237–263, Plenum Press, New York.
Kety, S. S., Javoy, F., Thierry, A. M., Julou, L., and Glowinski, J., 1967, A sustained effect of electroconvulsive shock on the turnover of norepinephrine in the central nervous system of the rat, Proc. Natl. Acad. Sci. U.S.A. 58:1249–1254.
Klaiber, E. L., Kobayashi, Y., Broverman, D. M., and Hall, F., 1971, Plasma monoamine oxidase activity in regularly menstruating women and in amenorrheic women receiving cyclic treatment with estrogenes and a progestin, J. Clin. Endocrinol. 33:630–638.
Klaiber, E. L., Broverman, D. M., Vogel, W., Kobayashi, Y., and Moriarty, D., 1972, Effects of estrogen therapy on plasma MAO activity and EEG driving responses of depressed women, Am. J. Psychiatry128:42–48.
Kleinberg, D. L., Noel, G. L., and Frantz, A. G., 1971, Chlorpromazine stimulation and L-dopa suppression of plasma prolactin in man, J. Clin. Endocrinol. Metab. 33:873–876.
Klerman, G. L., Schildkraut, J. J., Hasenbush, L. L., Greenblatt, M., and Friend, D. G., 1963, Clinical experience with dihydroxyphenylalanine (dopa) in depression, J. Psychiatr. Res. 1:289–297.
Kline, N. S., Sacks, W., and Simpson, G. M., 1964, Further studies on one day treatment of depression with 5-HTP, Am. J. Psychiatry121:379–381.
Knox, W. E., 1951, Two mechanisms which increase in vivo the liver tryptophan peroxidase activity: Specific enzyme adaption and stimulation of the pituitary adrenal system, Br. J. Exp. Pathol. 32:462–469.
Knox, W. E., and Auerbach, V. H., 1955, The hormonal control of tryptophan peroxidase in the rat, J. Biol. Chem. 214:307–313.
Koe, B. K., and Weissman, A., 1966, Marked depletion of brain serotonin by p-chlorophenylalanine, Fed. Proc. Fed. Am. Soc. Exp. Biol. 25:452.
Korf, J., and van Praag, H. M., 1970, The intravenous probenecid test: A possible aid in evaluation of the serotonin hypothesis on the pathogenesis of depression, Psychopharmacologia18:129–132.
Korf, J., van Praag, H. M., 1971, Amine metabolism in human brain: Further evaluation of the probenecid test, Brain Res. 35:221–230.
Korf, J., van Praag, H. M., 1972, Action of p-chloramphetamine on cerebral serotonin metabolism: An hypothesis, Neuropharmacology11:141–144.
Korf, J., van Praag, H. M., and Sebens, J. B., 1971, Effect of intravenously administered probenecid in humans on the levels of 5-hydroxy-indole-acetic acid, homovanillic acid and 3-methoxy-4-hydroxy-phenyl-glycol in cerebrospinal fluid, Biochem. Pharmacol. 20:659–668.
Korf, J., van Praag, H. M., and Sebens, J. B., 1972, Serum tryptophan decreased, brain tryptophan increased and brain serotonin synthesis unchanged after probenecid loading, Brain Res.42:239–242.
Korf, J., Schutte, H. H., and Venema, K., 1973, A semi-automated fluorometric determination of 5-hydroxyindoles in the nanogram range, Anal. Biochem.53:146–153.
Korf, J., Venema, K., and Postema, F., 1974, Decarboxylation of exogenous L-5-hydroxy-tryptophan after destruction of the cerebral raphe system, J. Neurochem.23:249–252.
Kupfer, D. Y., and Bowers, M. B., Jr., 1972, REM sleep and central monoamine oxidase inhibition, Psychopharmacologia27:183–190.
Kuriyama, K., and Speken, R., 1970, Effect of lithium on content and uptake of norepinephrine and 5-hydroxytryptamine in mouse brain synaptosomes and mitochondria, Life Sci. 9:1213–1220.
Lackroy, G. H., and van Praag, H. M., 1971, Lithium salts as sedatives. An investigation into the possible effects of lithium on acute anxiety, Acta Psychiatr. Scand.47:163–173.
Ladisisch, W., Steinhauff, N., and Matussek, N., 1969, Chronic administration of electroconvulsive shock and norepinephrine metabolism in the rat brain, Psychopharmacologia15:296–304.
Lakke, J. P. W. F., Korf, J., van Praag, H. M., and Schut, T., 1972, The predictive value of the probenecid test for the effect of levodopa therapy in Parkinson’s disease, Nature (London) New Biol. 236:208–209.
Lamprecht, F., Ebert, M. H., Turek, I., and Kopin, I. J., 1974, Serum dopamine-beta-hydroxylase in depressed patients and the effect of electroconvulsive shock treatment, Psychopharmacologia40:241–248.
Lapin, I. P., and Oxenkrug, G. F., 1969, Intensification of the central serotonergic process as a possible determinant of the thymoleptic effect, Lancet1:132–136.
Levitt, M., Spector, S., Sjoerdsma, A., and Udenfriend, S., 1965, Elucidation of the rate-limiting step in norepinephrine biosynthesis in the perfused guinea pig heart, J. Pharmacol. Exp. Ther.148:1–8.
Lewander, T., and Sjöström, R., 1973, Increase in the plasma concentration of free tryptophan caused by probenecid in humans. Psychopharmacologia33:81–86.
Lipsett, D., Madras, B. K., Wurtman, R. J., and Munro, H. N., 1973, Serum tryptophan level after carbohydrate ingestion: Selective decline in non-albumin-bound tryptophan coincident with reduction in serum free fatty acids, Life Sci. 12:57–64.
Lloyd, K. J., Farley, I. J., Deck, J. H. N., and Hornykiewicz, O., 1974, Serotonin and 5-hydroxyindoleacetic acid in discrete areas of the brainstem of suicide victims and control patients, Adv. Biochem. Psychopharmacol.11:387–397.
Lopez-Ibor, A. J. J., Gutierrez, J. L. A., and Iglesias, M. L. M., 1973, Tryptophan and amitryptiline in the treatment of depression. A double blind study, Int. Pharmacopsychiatry8:145–151.
Lovenberg, W., Jéquir, E., and Sjoerdsma, A., 1968, Tryptophan hydroxylation in mammalian systems, Adv. Pharmacol.6A:21–36.
Maas, J. W., Fawcett, J. A., and Dekirmenjian, H., 1968, 3-Methoxy-4-hydroxyphenylglycol (MHPG) excretion in depressive states: Pilot study, Arch. Gen. Psychiatry19:129–134.
Maas, J. W., Dekirmenjian, H., and Fawcett, J., 1971, Catecholamine metabolism, depression and stress, Nature (London)230:330–331.
Maas, J. W., Fawcett, J. A., and Dekirmenjian, H., 1972, Catecholamine metabolism, depressive illness, and drug responses, Arch. Gen. Psychiatry26:252–262.
Maas, J. W., Dekirmanjian, H., and Jones, F., 1973a, The identification of depressed patients who have a disorder of NE metabolism and/or disposition, in: Frontiers in Catecholamine Research (E. Usdin and S. Snyder, eds.), pp. 1091–1096, Pergamon Press, New York.
Maas, J. W., Dekirmenjian, H., Garver, D., Redmon, D. E., Jr., and Landis, D. H., 1973b, Excretion of catecholamine metabolites following intraventricular injection of 6-hydroxydopamine in the Macaca speciosa, Eur. J. Pharmacol.23:121–130.
Mandell, A. J. (ed.), 1975, Neurobiological mechanisms of presynaptic metabolic adaptation and their organization: Implications for a pathophysiology of the affective disorders, in: Neurobiological Mechanism of Adaption and Behavior, pp. 219–235, Raven Press, New York.
Mangoni, A., 1974, The “kynurenine shunt” and depression, Adv. Biochem. Psychopharmacol.11:293–298.
Martin, J. B., 1973, Neural regulations of growth hormone secretion, N. Engl. J. Med.288:1384–1393.
Matussek, N., Pohlmeier, H., and Rüther, E., 1966, Die Wirkung von Dopa auf gehemmte Depressionen, Klin. Wochenschr.44:727–728.
Matussek, N., Benkert, O., Schneider, K., Otten, H., and Pohlmeier, H., 1970, Wirkung eines Decarboxylasehemmers (Ro 4–4602) in Kombination mit L-dopa auf gehemmte Depressionen, Arzneim.-Forsch.20:934–937.
McGabe, M. S., Reich, T., and Winokur, G., 1970, Methysergide as a treatment for mania, Am. J. Psychiatry127:354–356.
McNamee, H. B., Moody, J. P., and Naylor, G. J., 1972a, Indoleamine metabolism in affective disorders: Excretion of tryptamine, indoleacetic acid and 5-hydroxyindoleacetic acid in depressive states, J. Psychosom. Res.16:63–70.
McNamee, H. B., Le Poidevin, D., and Naylor, G. J., 1972b, Methysergide in mania: A double-blind comparison with thioridazine, Psychol. Med.2:66–69.
Meek, J. L., and Neff, N. H., 1973, Is cerebrospinal fluid the major avenue for the removal of 5-hydroxyindoleacetic acid from the brain?, Neuropharmacology12:497–499.
Meites, J., Lu, K. H., Wuttke, W., Welsch, C. W., Nagasawa, H., and Quadrie, F. K., 1972, Recent studies on function and control of prolactin secretion in rats, Recent Prog. Horm. Res.28:471–526.
Mendels, J., 1971, Relationship between depression and mania, Lancet1:342.
Mendels, J., and Frazer, A. J., 1973, Intracellular lithium concentration and clinical response: Towards a membrane theory of depression, J. Psychiatr. Res.10:9–18.
Mendels, J., Frazer, A., Fitzgerald, R. G., Ramsey, T. A., and Stokes, J. W., 1972, Biogenic amine metabolites in cerebrospinal fluid of depressed and manic patients, Science175:1380–1382.
Mendels, J., Stinnet, J. L., Burns, D., and Frazer, A., 1975, Amine precursors and depression, Arch. Gen. Psychiatry32:22–30.
Messiha, F. S., Agallianos, D., and Clower, C., 1970, Dopamine excretion in affective states and following Li2CO3 therapy, Nature (London)225:868–869.
Miller, E. E., Sawano, S., and Arimura, A., 1967, Blockade of release of growth hormone by brain norepinephrine depletors, Endocrinology80:471–476.
Modigh, K., 1972, Central and peripheral effects of 5-hydroxytryptophan on motor activity in mice, Psychopharmacologia23:48–54.
Modigh, K., 1973, Effects of L-tryptophan on motor activity in mice, Psychopharmacologia30:123–134.
Moir, A. T. B., Ashcroft, G. W., Crawford, T. B. B., Eccleston, D., and Guildberg, H. C., 1970, Cerebral metabolites in cerebrospinal fluid as a biochemical approach to the brain, Brain93:357–368.
Morgan, W. W., Saldana, J. J., Yndo, C. A., and Morgan, J. F., 1975, Correlations between circadian changes in serum amino acids or brain tryptophan and the contents of serotonin and 5-hydroxyindoleacetic acid in regions of the rat brain, Brain Res. 84:75–86.
Mosnaim, A. D., Inwang, E. E., and Sabelli, H. C., 1974, The influence of psychotropic drugs on the levels of endogenous 2-phenylethylamine in rabbit brain, Biol. Psychiatry8:227–234.
Mountjoy, C. Q., Price, J. S., Weller, M., Hunter, P., Hall, R., and Dewar, J. H., 1974, A double-blind cross-over sequential trial of oral thyrotropin-releasing hormone in depression, Lancet1:958–960.
Müller, E. E., Pecile, A., Felici, M., and Cocchi, D., 1970, Norepinephrine and dopamine injection into lateral brain ventricles of the rat and growth hormone releasing activity in hypothalamus and plasma, Endocrinology86:1376–1382.
Murphy, D. L., 1972, Amine precursors, amines, and false neurotransmitters in depressed patients, Am. J. Psychiatry129:141–148.
Murphy, D. L., and Weiss, R., 1972, Reduced monoamine oxidase activity in blood platelets from bipolar depressed patients, Am. J. Psychiatry128:35–41.
Murphy, D. L., Colburn, R. W., Davis, J. M., and Bunney, W. E., Jr., 1969, Stimulation by lithium of monoamine uptake in human platelets, Life Sci. 8:1187–1193.
Murphy, D. L., Brodie, H. K. H., Goodwin, F. K., and Bunney, W. E., Jr., 1971, L-Dopa: Regular induction of hypomania in “bipolar” manic depressive patients, Nature (London)229:135–136.
Murphy, D. L., Baker, M., Goodwin, F. K., Miller, H., Kotin, J., and Bunney, W. E., Jr., 1974, L-Tryptophan in affective disorders: Indoleamine changes and differential clinical effects, Psychopharmacologia34:11–20.
Musacchio, J. M., Julou, L., Kety, S. S., and Glowinski, J., 1969, Increase in rat brain tyrosine hydroxylase activity produced by electroconvulsive shock, Proc. Nat. Acad. Sci. U.S.A.63:1117–1119.
Nagatsu, T., Hidaka, H., Kuzuya, H., and Takeya, K., 1970, Inhibition of dopamines-hydroxylase by fusaric acid (5-butylpicolinic acid) in vitro and in vivo, Biochem. Pharmacol.19:35–44.
Neff, N. H., and Yand, H. Y. T., 1974, Another look at the monoamine oxidases and the monoamine oxidase inhibitor drugs, Life Sci.14:2061–2077.
Neff, N. H., Tozer, T. H., and Brodie, B. B., 1967, Application of steady-state kinetics to studies of the transfer of 5-hydroxyindoleacetic acid from brain to plasma, J. Pharmacol. Exp. Ther.158:214–218.
Ng, K. Y., Chase, T. N., Colburn, R. W., and Kopin, I. J., 1970, L-Dopa induced release of cerebral monoamines, Science170:76–77.
Nordin, G., Ottosson, J. O., and Roos, B.-E., 1971, Influence of convulsive therapy on 5-hydroxyindoleacetic acid and homovanillic acid in cerebrospinal fluid in endogenous depression, Psychopharmacologia20:315–320.
Nybäck, H., and Sedvall, G., 1970, Further studies on the accumulation and disappearance of catecholamines formed from trysine-14C in mouse brain. Effect of some phenothiazine analogues, Eur. J. Pharmacol.10:193–205.
Olsson, R., and Roos, B.-E., 1968, Concentrations of 5-hydroxyindoleacetic acid and homovanillic acid in the cerebrospinal fluid after treatment with probenecid in patients with Parkinson’s disease, Nature (London)219:502–503.
Papeschi, R., and McClure, D. J., 1971, Homovanillic acid and 5-hydroxyindoleacetic acid in cerebrospinal fluid of depressed patients, Arch. Gen. Psychiatry25:354–358.
Papeschi, R., Sourkes, T. L., Poirier, L. J., and Boucher, R., 1971, On the intracerebral origin of homovanillic acid of the cerebrospinal fluid of experimental animals, Brain Res. 28:527–533.
Papeschi, R., Randrup, A., and Munkvad, I., 1974, Effect of ECT on dopaminergic and noradrenergic mechanisms, Psychopharmacologia35:159–168.
Pare, C. M. B., 1963, Potentiation of monoamine oxidase inhibitors by tryptophan, Lancet2:527:528.
Pare, C. M. B., and Sandler, M., 1959, A clinical and biochemical study of a trial of iproniazid in the treatment of depression, J. Neurol. Neurosurg. Psychiatry22:247–251.
Pare, C. M. B., Yeung, D. P. H., Price, K., and Stacey, R. S., 1969, 5-Hydroxytryptamine in brainstem, hypothalamus and caudate nucleus of controls and of patients committing suicide by coal-gas poisoning, Lancet2:133–135.
Paul, M. J., Ditzion, B. R., Pauk, G. L., and Janowski, D. S., 1970, Urinary adenosine 35′-monophosphate excretion in affective disorders, Am. J. Psychiatry126:1493–1497.
Paul, M. J., Cramer, H., and Goodwin, F. K., 1971, Urinary cyclic AMP excretion in depression and mania, Arch. Gen. Psychiatry24:327–333.
Paykel, E. S., 1972, Correlates of a depressive typology, Arch. Gen. Psychiatry27:203–210.
Perel, J. M., Black, N., Wjarton, R. N., and Malitz, S., 1969, Inhibition of imipramine metabolism by methylphenidate, Fed. Proc. Fed. Am. Soc. Exp. Biol.28:418.
Perez-Cruet, J., Tagliamonte, P., Tagliamonte, A., and Gessa, G. L., 1971, Stimulation of serotonin synthesis by lithium, J. Pharmacol. Exp. Ther.178:325–330.
Perris, C., 1966, A study of bipolar (manic-depressive) and unipolar recurrent depressive psychoses, Acta Psychiat. Scand.42(Suppl. 194): 1–189.
Persson, T., and Roos, B. E., 1968, 5-Hydroxytryptophan for depression, Lancet2:987–988.
Pflanz, G., and Palm, D., 1973, Acute enhancement of dopamine-β-hydroxylase activity in human plasma after maximum work load, Eur. J. Clin. Pharmacol.5:555–558.
Pletscher, A., Bartholini, G., Bruderer, H., Burkard, W. P., and Grey, K. F., 1964, Chlorinated aralkylamines affecting the cerebral metabolism of 5-hydroxytryptamine, J. Pharmacol. Exp. Ther.145:344–350.
Pletscher, A., da Prada, M., Burkard, W. P., Bartholini, G., Steiner, F. A., Bruderer, H., and Bigler, F., 1966, Aralkylamines with different effects on the metabolism of aromatic monoamines, J. Pharmacol. Exp. Ther.154:64–72.
Pletscher, A., Bartholini, G., and Tissot, R., 1967, Metabolic fate of 1-(14C) dopa in cerebrospinal fluid and blood plasma of humans, Brain Res. 4:106–109.
Plotnikoff, N. P., Prange, A. J., Jr., Breese, G. R., Anderson, M. S., and Wilson, I. C., 1972, Thyrotropin releasing hormone: Enhancement of dopa activity by a hypothalamic hormone, Science178:417–418.
Plotnikoff, N. P., Prange, A. J., Jr., Breese, G. R., and Wilson, I. C., 1974, Thyrotropin releasing hormone: Enhancement of dopa activity in thyroidectomized rates, Life Sci.14:1271–1278.
Poitou, P., Guerinot, F., and Bohuon, C., 1974, Effect of lithium on central metabolism of 5-hydroxytryptamine, Psychopharmacologia38:75–80.
Poldinger, W., 1963, Combined administration of desipramine and reserpine or tetrabenazine in depressed patients, Psychopharmacologia4:308.
Post, R. M., and Goodwin, F. K., 1973, Stimulated behavior states: An approach to specificity in psychobiological research, Biol. Psychiatry7:237–254.
Post, R. M., Goodwin, F. K., Gordon, E., and Watkins, D. M., 1973a, Amine metabolites in human cerebrospinal fluid: Effects of cord transaction and spinal fluid block, Science179:897–899.
Post, R. M., Kotin, J., Goodwin, F. K., and Gordon, E. K., 1973b, Psychomotor activity and cerebrospinal fluid amine metabolites in affective illness, Am. J. Psychiatry130:67–72.
Post, R. M., Gordon, E. K., Goodwin, F. K., Bunney, W. E., Jr., 1973c, Central norepinephrine metabolism in affective illness. MHPG in the cerebrospinal fluid, Science179:1002–1003.
van Praag, H. M., 1962, A critical investigation of the importance of monoamine oxidase inhibition as a therapeutic principle in the treatment of depression, thesis, Utrecht.
van Praag, H. M., 1967, Antidepressants, catecholamines and 5-hydroxyindoles. Trends towards a more specific research in the field of antidepressants, Psychiatr. Neurol. Neurochir.70:219–233.
van Praag, H. M., 1969, Depressie en de stofwisseling van 5-hydroxytryptamine (Depression and serotonin metabolism), Ned. Tijdschr. Geneeshd.113:2245–2247.
van Praag, H. M., 1972, Biological psychiatry in perspective. The dangers of sectarianism in psychiatry, Comp. Psychiatry13:401–410.
van Praag, H. M., 1974, Central monoamine deficiency in depressions: Causative or secundary phenomenon, Pharmakopsychiatr.8:321–326.
van Praag, H. M., 1974a, Towards a biochemical typology of depressions? Pharmacopsychiatry7:281–292.
van Praag, H. M., 1974b, New developments in human psychopharmacology, Comp. Psychiatry15:389–401.
van Praag, H. M., 1975, Neuroleptics as a guideline to biological research in psychotic disorders, Comp. Psychiatry16:7–22.
van Praag, H. M., 1977a, Depression and Schizophrenia: A Contribution on Their Chemical Pathologies, Spectrum, New York.
van Praag, H. M., 1977b, Evidence of serotonin-deficient depressions, Neuropsychobiology3:56–63.
van Praag, H. M., 1978, Psychotropic Drugs. A Guideline for the Practising Physician, Brunner/Masel, New York.
van Praag, H. M., and Korf, J., 1970, L-Tryptophan in depression, Lancet2:612.
van Praag, H. M., and Korf, J., 1971a, Endogenous depressions with and without disturbances in the 5-hydroxytryptamine metabolism: A biochemical classification?, Psychopharmacologia19:148–152.
van Praag, H. M., and Korf, J., 1971b, Nieuwe ontwikkelingen op het terrein van de antidepressiva (New developments in the field of antidepressants), Ned. Tijdschr. Geneeshd.115:1963–1970.
van Praag, H. M., and Korf, J., 1971c, Retarded depressions and the dopamine metabolism, Psychopharmacologia19:199–203.
van Praag, H. M., and Korf, J., 1973, 4-Chloramphetamines. Chance and trend in the development of new antidepressants, J. Clin. Pharmacol.13:3–14.
van Praag, H. M., and Korf, J., 1974, 5-Hydroxytryptophan as an antidepressant, J. Nerv. Ment. Dis.158:331–337.
van Praag, H. M., and Korf, J., 1975, Neuroleptics, catecholamines and psychotic disorders. A study of their interrelation, Am. J. Psychiatry132:593–599.
van Praag, H. M., and Korf, J., 1975a, 4-Chloramphetamines, in: Psychotherapeutic Drugs (E. Usdin and I. S. Forrest, eds.), pp. 1217–1250, Marcel Dekker, New York and Basel.
van Praag, H. M., and Korf, J., 1975b, Biochemical research in schizophrenia. Results of a new research strategy, Acta Psychiatr. Scand.51:268–284.
van Praag, H. M., and Leijnse, B., 1963a, Die Bedeutung der Monoaminoxydasehemmung als antidepressives Prinzip I, Psychopharmacologia4:1–14.
van Praag, H. M., and Leijnse, B., 1963b, Die Bedeutung der Psychopharmacologie für die klinische Psychiatrie. Systematik als notwendiger Ausgangspunkt, Nervenarzt34:530–537.
van Praag, H. M., and Leijnse, B., 1965, Neubewertung des Syndromes. Skizze einer funktionellen Pathologie, Psychiatr. Neurol. Neurochir.68:50–66.
van Praag, H. M., Uleman, A. M., and Spitz, J. C., 1965, The vital syndrome interview. A structured standard interview for the recognition and registration of the vital depressive symptom complex, Psychiatr. Neurol. Neurochir.68:329–346.
van Praag, H. M., Korf, J., and Puite, J., 1970, 5-Hydroxyindoleacetic acid levels in the cerebrospinal fluid of depressive patients treated with probenecid, Nature (London)225:1259–1260.
van Praag, H. M., Korf, J., Dols, L. C. W., and Schut, T., 1972, A pilot study of the predictive value of the probenecid test in application of 5-hydroxytryptophan as an antidepressant, Psychopharmacologia25:14–21.
van Praag, H. M., Korf, J., and Schut, T., 1973a, Cerebral monoamines and depression An investigation with the probenecid technique, Arch. Gen. Psychiatry28:827–831.
van Praag, H. M., Flentge, F., Korf, J., Dols, L. C. W., and Schut, T., 1973b, The influence of probenecid in the metabolism of serotonin, dopamine and their precursors, in man, Psychopharmacologia33:141–151.
van Praag, H. M., van den Burg, W., Bos, E. R. M., and Dols, L. C. W., 1974, 5-Hydroxytryptophan in combination with clomipramine in “therapy-resistant” depressions, Psychopharmacologia30:267–269.
van Praag, H. M., Korf, J., Lakke, J. P. W. F., and Schut, T., 1975a, Dopamine metabolism in depression, psychosis and Parkinson’s disease or: The problem of the specificity of biochemical variables in behavior disorders, Psychol. Med.5:138–146.
van Praag, H. M., Dols, L. C. W., and Schut, T., 1975b, Biochemical versus psychopathological action profile of neuroleptics. A comparative study of chlorpromazine and oxypertine in acute psychotic disorders, Compr. Psychiatry16:255–263.
Prange, A. J., Jr., McCurdy, L. R., and Cochrane, C. M., 1967, The systolic blood pressure response of depressed patients to infused norepinephrine, J. Psychiatr. Res.5:1–13.
Prange, A. J., Jr., Wilson, I. C., Knox, A., McClane, T. K., and Lipton, M. A., 1970, Enhancement of imipramine by thyroid stimulating hormone: Clinical and theoretical implications, Am. J. Psychiatry127:191–199.
Prange, A. J., Jr.,Wilson, I. C., Lara, P. P., Alltop, L. B., and Breese, G. R., 1972a, Effects of thyrotropin-releasing hormone in depression, Lancet2:999–1002.
Prange, A. J., Jr., Wilson, I. C., Knox, A. E., McClane, T. K., Breese, G. R., Martin, B. R., Alltop, L. B., and Lipton, M. A., 1972b, Thyroid-imipramine clinical and chemical interaction: Evidence for a receptor deficit in depression, J. Psychiatr. Res.9:187–205.
Prange, A. J., Jr., Wilson, I. C., Lynn, C. W., Alltop, L. B., Stikeleather, R. A., and Raleigh, N. C., 1974, L-Tryptophan in mania, Arch. Gen. Psychiatry30:52–62.
Pritchard, B. N. C., Johnston, A. W., Hill, I. D., and Rosenheim, M. L., 1968, Bethanidine, guanethidine, and methyldopa in the treatment of hypertension: A within-patient comparison, Br. Med. J.1:135–144.
Prockop, L., Fahn, S., and Barbour, P., 1974, Homovanillic acid: Entry rate kinetics for transfer from plasma to cerebrospinal fluid, Brain Res. 80:435–422.
Puite, J. K., Schut, T., van Praag, H. M., and Lakke, J. P. W. F., 1973, Monoamine metabolism and depression in Parkinson patients, Psychiatr. Neurol. Neurochir. 76:61–70.
Ramsden, E. N., 1970, Cyclic AMP in depression and mania, Lancet2:108.
Redmond, E. E., Jr., Maas, J. W., Kling, A., Graham, C. W., and Dekirmenjian, H., 1971, Social behavior of monkeys selectively depleted of monoamines, Science174:428–430.
Rees, J. R., Alltop, M. N. E., and Hullin, R. P., 1974, Plasma concentrations of tryptophan and other amino acids in manic-depressive patients, Psychol. Med.4:334–337.
Reigle, T. G., Avni, J., Platz, P. A., Schildkraut, J. J., and Plotnikoff, N. P., 1974, Norepinephrine metabolism in the rat brain following acute and chronic administration of thyrotropin-releasing hormone, Psychopharmacologia37:1–6.
Rimon, R., and Räkköläinen, V., 1968, Lithium iodide in the treatment of confusional states, Br. J. Psychiatry114:109–110.
Rimon, R., Roos, B.-E., Räkköläinen, V., and Alane, Y., 1971, The content of 5-hydroxyindoleacetic acid and homovanillic acid in the cerebrospinal fluid of patients with acute schizophrenia, J. Psychosom. Res.15:375–378.
Robins, E., Munoz, R. A., Martin, S., and Gentry, K. A., 1972, Primary and secondary affective disorders, in: Disorders of Mood (J. Zubin and F. A. Freyhan, eds.), pp. 33–45, John Hopkins Press, Baltimore.
Robinson, D. S., Davis, J. M., Nies, A., Ravaris, C. G., and Sylwester, D., 1971, Relation of sex and aging to monoamine oxidase activity of human brain, plasma and platelets, Arch. Gen. Psychiatry24:536–539.
Robinson, D. S., Davis, J. M., Nies, A., Colburn, R. W., Davis, J. N., Bourne, H. R., Bunney, W. E., Jr., Shaw, D. M., and Coppen, A. J., 1972, Ageing, monoamines, and monoamine oxidase levels, Lancet1:290–291.
Robison, G. A., Coppen, A. J., Whybrow, P. C., and Prange, A. J., Jr., 1970, Cyclic AMP in affective disorders, Lancet2:1028–1029.
Roos, B.-E., and Sjöström, R., 1969, 5-Hydroxyindoleacetic acid and homovanillic acid levels in the cerebrospinal fluid after probenecid application in patients with manic-depressive psychosis, J. Clin. Pharmacol.1:153–155.
van Rossum, J. M., 1967, The significance of dopamine receptor blockade for the action of neuroleptic drugs, in: Neuropsychopharmacology (H. Brill, ed.), pp. 321–329, Excerpta Medica, The Hague.
Roth, J. A., and Gillis, C. N., 1974, Deamination of β-phenylethylamine by monoamine oxidase-inhibition by imipramine, Biochem. Pharmacol.23:2537–2545.
Rubin, R. T., 1967, Adrenal cortical activity changes in manic-depressive illness, Arch. Gen. Psychiatry17:671–679.
Rubin, R. T., Miller, R. G., Clark, B. R., Poland, R. E., and Arthur, R. J., 1970, The stress of aircraft carrier landings. II. 3-Methoxy-4-hydroxyphenylglycol excretion in naval aviators, Psychosom. Med.32:589–597.
Rutledge, C. O., 1970, The mechanisms by which amphetamine inhibits oxidative deamination of norepinephrine in brain, J. Pharmacol. Exp. Ther.171:188–195.
Sabelli, H. C., and Mosnaim, A. D., 1974, Phenylethylamine hypothesis of affective behavior, Am. J. Psychiatry131:695–699.
Sachar, E. J., 1967, Corticosteroids in depressive illness. I. A re-evaluation of control issues and the literature, Psychosom. Med.30:162–171.
Sachar, E. J., Frantz, A. G., Altman, N., and Sassin, J., 1973, Growth hormone and prolactin in unipolar and bipolar depressed patients: Response to hypoglycemia and l- dopa, Am. J. Psychiatry130:1362–1367.
Sack, R. L., and Goodwin, F. K., 1974, Inhibition of dopamine-β-hydroxylase in manic patients, Arch. Gen. Psychiatry31:649–654.
Sanders-Bush, E., and Sulser, F., 1970, p-Chloroamphetamine: In vivo investigations on the mechanism of the action of the selective depletion of cerebral serotonin, J. Pharmacol. Exp. Ther.175:419–426.
Sanders-Bush, E., Bushing, J. A., and Sulser, F., 1972, p-Chloroamphetamine-inhibition of cerebral tryptophan hydroxylase, Biochem. Pharmacol.21:1501–1510.
Sandler, M., Carter, S. B., Cuthbert, M. F., and Pare, C. M. B., 1975, Is there an increase in monoamine-oxidase activity in depressive illness?, Lancet1:1045–1048.
Sano, I., 1972, L-5-Hydroxytryptophan (L-5-HTP)-Therapie bei endogener Depression, Münch. Med. Wochenschr.144:1713–1716.
Schanberg, S. M., Schildkraut, J. J., Breese, G. R., and Kopin, I. J., 1968, Metabolism of normetanephrine H3 in rat brain: Identification of conjugated 3-methoxy-4-hydroxy-phenylglycol as major metabolite, Biochem. Pharmacol.17:247–254.
van Scheijen, J. D., 1971, Behandeling van manie met methysergide (Treatment of mania with methysergide), Ned. Tijdschr. Geneeskd.115:1634–1637.
van Scheijen, J. D., van Praag, H. M., and Korf, J., 1977, A controlled study comparing nomifensine and clomipramine in unipolar depression, using the probenecid technique, Br. J. Clin. Pharmacol.4:1795–1845.
Schildkraut, J. J., 1965, The catecholamine hypothesis of affective disorders: A review of supporting evidence, Am. J. Psychiatry122:509–522.
Schildkraut, J. J., 1973a, Pharmacology—the effects of lithium on biogenic amines, in: Lithium: Its Role in Psychiatric Research and Treatment (S. Gershon and B. Shopsin, eds.), pp. 51–73, Plenum Press, New York.
Schildkraut, J. J., 19736, Norepinephrine metabolites as biochemical criteria for classifying depressive disorders and predicting responses to treatment: Preliminary findings, Am. J. Psychiatry130:695–698.
Schildkraut, J. J., 1974, Biochemical criteria for classifying depressive disorders and predicting responses to pharmacotherapy; preliminary findings from studies of norepinephrine metabolism, Pharmacopsychiatry7:98–107.
Schildkraut, J. J., 1975, Depressions and biogenic amines, in: American Handbook of Psychiatry, Vol. VI (D. Hamburg, ed.), pp. 609–672, Basic Books, New York.
Schildkraut, J. J., and Draskoczy, P. R., 1974, Effects of electroconvulsive shock on norepinephrine turnover and metabolism: Basic and clinical studies, in: Psychobiology of Convulsive Therapy (M. Fink, S. Kety, J. McGaugh, and T. A. Williams, eds.), pp. 143–170, J. Wiley and Sons, New York.
Schildkraut, J. J., and Kety, S. S., 1967, Biogenic amines and emotion, Science 156:21–30.
Schildkraut, J. J., Klerman, G. L., Friend, D. G., and Greenblatt, M., 1963, Biochemical and pressor effects of oral D,L-dihydroxyphenylalanine in patients pretreated with antidepressant drugs, Ann. N. Y. Acad. Sci.107:1005–1015.
Schildkraut, J. J., Green, R., Gordon, E. K., and Durell, J., 1966, Normetanephrine excretion and affective state in depressed patients treated with imipramine, Am. J. Psychiatry123:690–700.
Schildkraut, J. J., Schanberg, S. M., Breese, G. R., and Kopin, I. J., 1967, Norepinephrine metabolism and drugs used in the affective disorders: A possible mechanism of action, Am. J. Psychiatry124:600–608.
Schildkraut, J. J., Logue, M. A., and Dodge, G. A., 1969, Effects of lithium salts on turnover and metabolism of norepinephrine in rat brain, Psychopharmacologia14:135–141.
Schou, M., 1973, Prophylactive lithium maintenance treatment in recurrent endogenous affective disorders, in: Lithium: Its Role in Psychiatric Research and Treatment (S. Gershon and B. Shopsin, eds.), pp. 269–294, Plenum Press, New York.
Schubert, J., 1973, Effect of chronic lithium treatment on monoamine metabolism in rat brain, Psychopharmacologia32:301–311.
Schubert, J., Nyback, H., and Sedvall, G., 1970, Effect of antidepressant drugs on accumulation and disappearance of monoamines formed in vivo from labelled precursors in mouse brain, J. Pharm: Pharmacol.22:136–139.
Schuckit, M., Robins, E., and Feighner, J., 1971, Tricyclic antidepressants and monoamine oxidase inhibitors, Arch. Gen. Psychiatry24:509–514.
Sebens, J. B., and Korf, J., 1975, Cyclic AMP in cerebrospinal fluid: Accumulation following probenecid and biogenic amines, Exp. Neurol.46:333–344.
Sethna, E. R., 1974, A study of refractory cases of depressive illnesses and their response to combined antidepressant treatment, Br. J. Psychiatry124:265–272.
Shaw, D. M., 1975, Lithium and amine metabolism, in: Lithium: Research and Therapy F. N. Johnson, ed.), pp. 411–423, Academic Press, New York.
Shaw, D. M., Camps, F. E., and Eccleston, E. G., 1967, 5-Hydroxytryptamine in hind-brain of depressive suicides, Br. J. Psychiatry, 113:1407–1411.
Shaw, D. M., O’Keeffe, R., MacSweeney, D. A., Brooksbank, B. W. L., Noguera, R., and Coppen, A., 1973, 3-Methoxy-4-hydroxyphenylglycol in depression, Psychol. Med. 3:333–336.
Sheard, M. H., and Aghajanian, G. K., 1968, Stimulation of the midbrain raphe: Effect on serotonin metabolism, J. Pharmacol. Exp. Ther.163:425–430.
Sheard, M., and Aghajanian, G. K., 1970, Neuronally activated metabolism of brain serotonin: Effect of lithium, Life Sci. 9:285–290.
Sheard, M., Lolovick, A., and Aghajanian, J. K., 1972, Raphe neurons: Effect of tricyclic antidepressant drugs, Brain Res. 43:690–694.
Shibuya, T., and Andersson, E. G., 1968, The influence of chronic cord transection on the effects of 5-hydroxytryptophan, L-tryptophan and pargyline on spinal neuronal activity, J. Pharmacol. Exp. Ther.164:185–190.
Shields, P. J., and Eccleston, D., 1972, Effects of electrical stimulation of rat midbrain on 5-hydroxytryptamine synthesis as determined by a sensitive radioisotope method, J. Neurochem.19:265–272.
Shopsin, B., Freedman, L. S., Goldstein, M., and Gershon, S., 1972, Serum dopamine-β-hydroxylase (DBH) activity and affective states, Psychopharmacologia27:11–16.
Shopsin, B., Wilk, S., Gershon, S., Davis, K., and Suhl, M., 1973a, Cerebrospinal fluid MHPG. An assessment of norepinephrine metabolism in affective disorders, Arch. Gen. Psychiatry28:230–233.
Shopsin, B., Gershon, S., Goldstein, M., Friedman, E., and Wilk, S., 1974, Use of synthesis inhibition in defining a role for biogenic amines during imipramine treatment in depressed patients, Psychopharmacol. Bull.10:52.
Shore, P. A., and Brodie, B. B., 1957, LSD-like effects elicited by reserpine in rabbits pretreated with iproniazid, Proc. Soc. Exp. Biol. Med.94:433–435.
Sinanan, K., Reatine, A. M. B., Beckett, P. G. S., and Love, W. C., 1975, Urinary cyclic AMP in “endogenous” and “neurotic” depression, Br. J. Psychiatry126:49–55.
Sjoerdsma, A., Engelman, K., Spector, S., and Udenfriend, S., 1965, Inhibition of catecholamine synthesis in man with alpha-methyl-tyrosine, an inhibitor of tyrosine hydroxylase, Lancet2:1092–1094.
Sjöström, R., 1972, Steady-state levels of probenecid and their relation to acid monoamine metabolites in human cerebrospinal fluid, Psychopharmacologia25:96–100.
Sjöström, R., and Roos, B.-E., 1972, 5-Hydroxyindoleacetic acid and homovanillic acid in cerebrospinal fluid in manic-depressive psychosis, Eur. J. Clin. Pharmacol.4:170–176.
Sloane, R. B., Hughes, W., and Haust, H. L., 1966, Catecholamine excretion in manic-depressive and schizophrenic psychosis and its relationship in symptomatology, Can. Psychiatr. Assoc. J. 11:6–19.
Snaith, R. P., and McCoubrie, M., 1974, Antihypertensive drugs and depression, Psychol. Med.4:393–398.
Snowdon, J., and Braithwaite, R., 1974, Combined antidepressant medication, Br. J. Psychiatry125:610–611.
Snyder, S. H., 1972, Catecholamines in the brain as mediators of amphetamine psychosis, Arch. Gen. Psychiatry27:169–179.
Sonninen, V., Riekkinen, P., and Rinne, U. K., 1973, Acid monoamine metabolites in cerebrospinal fluid and multiple sclerosis, Neurology23:760–763.
Sourkes, T. L., 1965, The action of α-methyldopa in the brain, Br. Med. Bull.21:66–69.
Sourkes, T. L., 1973a, Enzymology and sites of action of monoamines in the central nervous system, Adv. Neurol.2:13–35.
Sourkes, T. L., 1973b, On the origin of homovanillic acid (HVA) in the cerebrospinal fluid, J. Neurol. Transm.34:153–157.
Sourkes, T. L., Murphy, G. F., and Chavez, B., 1961, The action of some alpha-methyl and other amino acids on cerebral catecholamines, J. Neurochem.8:109–115.
Spector, S., Sjoerdsma, A., and Udenfriend, S., 1965, Blockade of endogenous norepinephrine synthesis by alpha-methyltyrosine, an inhibitor of tyrosine hydroxylase, J. Pharmacol. Exp. Ther.147:86–95.
Stein, L., and Wise, C. D., 1971, Possible etiology of schizophrenia: Progressive damage to the noradrenergic reward system by 6-hydroxy-dopamine, Science171:1032–1036.
Ström-Olsen, R., and Weil-Malherbe, H., 1958, Humoral changes in manic-depressive psychosis with particular reference to excretion of catecholamines in urine, J. Mental Sci.104:696–704.
Sulser, F., and Sanders-Bush, E., 1971, Effects of drugs on amines in the CNS, Annu. Rev. Pharmacol.11:209–230.
Sulser, F., Owens, M. L., Norvich, M. R., and Dingell, J. V., 1968, Relative role of storage and synthesis of brain norepinephrine in psychomotor stimulation evoked by amphetamine or by desimipramine and tetrabenazine, Psychopharmacologia12:322–332.
Tagliamonte, A., Tagliamonte, P., Perez-Cruet, J., and Gessa, G. L., 1971a, Increase of brain tryptophan caused by drugs which stimulate serotonin synthesis, Nature (London) New Biol. 299:125–126.
Tagliamonte, A., Tagliamonte, P., Perez-Cruet, J., Stern, S., and Gessa, G. L., 1971b, Effect of psychotropic drugs on tryptophan concentration in the rat brain, J. Pharmacol. Exp. Ther.177:475–480.
Takahashi, R., Nagao, Y., Tsuchiya, K., Takamizawa, M., and Kobayashi, T., 1968a, Catecholamine metabolism of manic-depressive illness, J. Psychiatr. Res.6:185–199.
Takahashi, R., Utenza, H., Machiyama, Y., Kurihama, M., Otsuka, T., Nakamura, T., and Konamura, H., 1968b, Tyrosine metabolism in manic-depressive illness, Life Sci. Part II7:1219–1231.
Takahashi, R., Kondo, H., Yoshimura, M., and Ochi, Y., 1973, Antidepressant effect of thyrotropin-releasing hormone (TRH) and the plasma thyrotropin levels in depression, Folia Psychiatr. Neurol. Jpn.27:305–314.
Takahashi, R., Kondo, H., and Kato, N., 1975, Effect of L-5-hydroxytryptophan on brain monoamine metabolism and evaluation of its clinical effects in depressed patients, J. Psychiatr. Res.12:177–187.
Tamarkin, N. R., Goodwin, F. K., and Axelrod, J., 1970, Rapid elevation of biogenic amine metabolites in human CSF following probenecid, Life Sci. 9:1397–1408.
Thierry, A. M., Fekete, M., and Glowinski, J., 1968a, Effects of stress on the metabolism of noradrenaline, dopamine and serotonin (5-HT) in the central nervous system of the rat. II. Modifications of serotonin metabolism, Eur. J. Clin. Pharmacol.4:384–389.
Thierry, A. M., Javoy, F., Glowinski, J., and Kety, S. S., 1968b, Effects of stress on the metabolism of norepinephrine, dopamine and serotonin in the central nervous system of the rat. II. Modifications of norepinephrine turnover, J. Pharmacol. Exp. Ther.163:163–171.
Thoenen, H., 1972, Comparison between the effect of neuronal activity and nerve growth factor on the enzymes involved in the synthesis of norepinephrine, Pharmacol. Rev.24:255–267.
Thoenen, H., Haefely, W., Gey, K. F., and Hürlimann, A., 1965, Diminished effects of sympathetic nerve stimulation in cats pretreated with disulfiram: Liberation of dopamine as sympathetic transmitter, Life Sci. 4:2033–2038.
Tissot, R., 1962, Connaissances experimentales sur les monoamines et quelques syndromes psychiatriques, in: Monoamines et Systéme Nerveus Central (J. de Ajuriaguerra, ed.), pp. 169–207, Georg & Cie, Geneva.
Toivola, P. T. K., and Gale, C. C., 1972, Stimulation of growth hormone release by microinjection of norepinephrine into hypothalamus of baboons, Endocrinology90:895–902.
Trimble, M., Chadwick, D., Reynolds, E. H., and Marsden, C. D., 1975, L-5-Hydroxytryptophan and mood, Lancet1:583.
Turner, W. J., and Merlis, S., 1964, A clinical trial of pargyline and dopa in psychotic subjects, Dis. Nerv. Syst.25:538–541.
Udenfriend, S., 1966, Tyrosine hydroxylase, Pharmacol. Rev.18:43–51.
Voigtlander, P. F. von, and Moore, K. E., 1970, Behavioral and brain catecholamine depleting actions of V-14, 624, an inhibitor of dopamines-hydroxylase, Proc. Soc. Exp. Biol. Med.133:817–820.
Waal, H. J., 1967, Propranolol-induced depressions, Br. Med. J.1:50.
Wålinder, J., Skott, A., Nagy, A., Carlsson, A., and Roos, B. E., 1975, Potentiation of antidepressant action of clomipramine by tryptophan, Lancet1:984.
Weir, R. L., Chase, T. N., Ng, L. K. Y., and Kopin, I. J., 1973, 5-Hydroxyindoleacetic acid in spinal fluid: Relative contribution from brain and spinal cord, Brain Res. 52:409–412.
Weiss, B. L., Kupfer, D. J., Foster, F. G., and Delgado, J., 1974, Psychomotor activity, sleep and biogenic amine metabolites in depression, Biol. Psychiatry9:45–54.
Werdinius, B., 1967a, Elimination of 3,4-dihydroxyphenylacetic acid from the blood, Acta Pharmacol. Toxicol.25:9–17.
Werdinius, B., 1967b, Effect of probencid on the levels of monoamine metabolites in the rat brain, Acta Pharmacol. Toxicol.25:18–23.
Westerink, B. H. C., and Korf, J., 1975, Determination of nanogram amounts of homovanillic acid in the central nervous system with a rapid semi-automated fluorometric method, Biochem. Med.12:106–115.
Wharton, R. N., Perel, J. M., Dayton, P. G., and Malitz, S., 1971, A potential clinical use for methylphenidate with tricyclic antidepressants, Am. J. Psychiatry127:1619–1625.
Wilk, S., Shopsin, B., Gershon, S., and Suhl, M., 1972, Cerebrospinal fluid levels of MHPG in affective disorders, Nature (London)235:440–441.
Wilson, I. C., Prange, A. J., Jr., Lara, P. P., Alltop, L. B., Stikeleather, R. A., Lipton, M. A., and Hill, C., 1973, TRH (lopremone): Psychobiological responses of normal women. I. Subjective experiences, Arch. Gen. Psychiatry29:15–21.
Winokur, G., Cadoret, R., Dorzab, J., and Baker, M., 1971, Depressive disease. A genetic study, Arch. Gen. Psychiatry24:135–144.
Winston, F., 1971, Combined antidepressant therapy, Br. J. Psychiatry118:301–304.
Wise, D. C., and Stein, L., 1973, Dopamine-beta-hydroxylase. Deficits in the brains of schizophrenic patients, Science181:344–347.
Wong, D. T., Horng, J. S., Bymaster, F. P., Hauser, K. L., and Molloy, B. B., 1974, A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine, Life Sci. 15:471–479.
Wooten, G. F., and Cardon, V. P., 1973, Plasma dopamines-hydroxylase activity (elevation in man during cold pressor test and exercise), Arch. Neurol.28:103–106.
Wurtman, R. J., Rose, C. M., Chou, C., and Larin, F. F., 1968, Daily rhythms in the concentrations of various amino acids in human plasma, N. Engl. J. Med.279:171–175.
Wurtman, R. J., Rose, C. M., Matthyse, S., Stephenson, J., and Baldessarini, R., 1970, l-Dihydroxyphenylalanine: Effect of 5-adenosylmethionine in brain, Science169:395–397.
Wyatt, R. J., Engelman, K., Kupfer, D. J., Fram, D. H., Sjoerdsma, A., and Snyder, F., 1970, Effects of L-tryptophan (a natural sedative) on human sleep, Lancet2:842–846.
Wyatt, R. J., Portnoy, B., Kupfer, D. J., Snyder, F., and Engelman, K., 1971, Resting plasma catecholamine concentrations in patients with depression and anxiety, Arch. Gen. Psychiatry24:65–70.
Youdim, M. B., Collins, G. G., Sandler, M. J., Bevan Jones, A. B., Pare, C. M. B., and Nicholson, W. J., 1972, Human brain: Monoamine oxidase, multiple forms and selective inhibitors, Nature (London)236:225–228.
Young, S. N., Lal, S., Martin, J. B., Ford, R. M., and Sourkes, T. L., 1973, 5-Hydroxyindoleacetic acid, homovanillic acid and tryptophan levels in CSF above and below a complete block of CSF flow, Psychiatr. Neurol. Neurochir.76:439–444.
Yuwiler, A., Geller, E., and Eiduson, S., 1959, Studies on 5-hydroxytryptophan decarboxylase. I. In vitro inhibition and substrate interaction, Arch. Biochem.80:162–173.
Zeidenberg, P., Perel, J. M., Kanzler, M., Wharton, R. N., and Malitz, S., 1971, Clinical and metabolic studies with imipramine in man, Am. J. Psychiatry127:1321–1326.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1978 Plenum Press, New York
About this chapter
Cite this chapter
van Praag, H.M. (1978). Amine Hypotheses of Affective Disorders. In: Iversen, L.L., Iversen, S.D., Snyder, S.H. (eds) Handbook of Psychopharmacology. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-3189-6_4
Download citation
DOI: https://doi.org/10.1007/978-1-4684-3189-6_4
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-3191-9
Online ISBN: 978-1-4684-3189-6
eBook Packages: Springer Book Archive